TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24478323

Group type: EXPERIMENTAL
Intervention: Exercise program (sensorimotor, endurance, and strength training twice a week for 36 weeks)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 61
Study: 22583635

Group type: EXPERIMENTAL
Intervention: Fluorescence cystoscopy
Number of subjects: 551

Group type: COMPARATOR
Intervention: White light cystoscopy
Number of subjects: 551
Study: 19171009

Group type: EXPERIMENTAL
Intervention: Two or more doses of sulfadoxine-pyrimethamine (SP)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Each increment in number of SP doses
Number of subjects: 1441
Study: 17573796

Group type: EXPERIMENTAL
Intervention: 32 tablets (48 g) of sodium phosphate (NaP)
Number of subjects: 481

Group type: COMPARATOR
Intervention: 2L polyethylene glycol (PEG) solution plus 4 (20 mg) bisacodyl tablets
Number of subjects: 481
Study: 15833091

Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate (100 mg per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topiramate (100 or 200 mg per day)
Number of subjects: 0
Study: 11812917

Group type: EXPERIMENTAL
Intervention: Epoetin alfa, 150-300 IU/kg or 10,000-20,000 IU, three times weekly
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Epoetin alfa, once-weekly dosing
Number of subjects: 7000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7000
Study: 9830579

Group type: EXPERIMENTAL
Intervention: Patients with cholelithiasis
Number of subjects: 500

Group type: COMPARATOR
Intervention: Patients without cholelithiasis
Number of subjects: 500
Study: 7662078

Group type: EXPERIMENTAL
Intervention: Otovent-supported middle ear aeration before and after adenoidectomy
Number of subjects: 146

Group type: COMPARATOR
Intervention: Adenoidectomy followed by paracentesis (Control)
Number of subjects: 146
Study: 2520419

Group type: EXPERIMENTAL
Intervention: Pulsed infrared laser treatment, 12 sessions on alternate days, total energy dose of 5 J each, targeting four painful muscular trigger points and five acupuncture points.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment, 12 sessions on alternate days, identical procedure to the intervention group but with nonoperational laser apparatus.
Number of subjects: 0
Study: 1036663

Group type: EXPERIMENTAL
Intervention: Diets containing proteins (3.0 g of N from rice plus 3.0 g of N from milk)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diets containing proteins (3.0 g of N from rice plus 3.0 g of N from wheat flour)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crystalline amino acids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diets containing amino acids instead of rice plus wheat
Number of subjects: 0
Study: 31851290

Group type: EXPERIMENTAL
Intervention: Prehospital transfusion of 2 U of plasma
Number of subjects: 626

Group type: COMPARATOR
Intervention: Standard care (crystalloid-based resuscitation)
Number of subjects: 626
Study: 30510604

Group type: EXPERIMENTAL
Intervention: P/F ratio ≤ 200 in the respiratory insufficiency group
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Intubation duration in the nonrespiratory insufficiency group
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: P/F ratio in the respiratory insufficiency group
Number of subjects: 262
Study: 27506222

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 1398

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 1398

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Number of subjects: 1398

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1398
Study: 24479254

Group type: EXPERIMENTAL
Intervention: Oculovestibular recoupling
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control
Number of subjects: 29
Study: 24261110

Group type: EXPERIMENTAL
Intervention: Periodic intra-operative phone calls every two hours
Number of subjects: 117

Group type: COMPARATOR
Intervention: No periodic phone calls
Number of subjects: 117
Study: 20804444

Group type: EXPERIMENTAL
Intervention: DPSGC 25 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 19128713

Group type: EXPERIMENTAL
Intervention: 10 mL of 10 mg/mL ropivacaine hydrochloride with epinephrine (n=19)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 10 mL of 2.5 mg/mL bupivacaine with epinephrine (n=20)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Saline with epinephrine (n=19)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Ropivacaine group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Bupivacaine group
Number of subjects: 58
Study: 16501426

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (80 mg/day)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Aspirin plus heparin (80 mg/day + 5000 IU unfractionated heparin subcutaneously 12 hourly)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Aspirin plus heparin
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Overall success rate
Number of subjects: 550
Study: 12871893

Group type: EXPERIMENTAL
Intervention: Post-menopausal hormone therapy (pHT) regimens including any estrogen, any estrogen plus any progestin, or tibolone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Tibolone (synthetic progestin)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Any estrogen compound
Number of subjects: 39
Study: 10952827

Group type: EXPERIMENTAL
Intervention: Pulsed Doppler measurements of mitral inflow velocities and early inflow deceleration time
Number of subjects: 3022
Study: 8793701

Group type: EXPERIMENTAL
Intervention: Non-pharmacological management (dietary therapy, restriction of alcohol consumption, exercise)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Non-pharmacological management (restriction of sodium intake, behavioral therapy)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Non-pharmacological management
Number of subjects: 100
Study: 1499708

Group type: EXPERIMENTAL
Intervention: Citric acid (90-100%)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Distilled water (74-84%)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Capsaicin (37-49%, at 2 microM)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Citric acid (100 mM)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Citric acid (300 mM)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Citric acid (1 M)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Capsaicin (3 microM)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Capsaicin (10, 30, 100 microM)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Capsaicin (100 microM)
Number of subjects: 33
Study: 6500764

Group type: EXPERIMENTAL
Intervention: Phenylbutazone 300 mg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen 1200 mg per day
Number of subjects: 0
Study: 31337122

Group type: EXPERIMENTAL
Intervention: Tart Cherry Juice (TC)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pomegranate Juice (POM)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Energy-matched fruit-flavored placebo drink
Number of subjects: 36
Study: 30478021

Group type: EXPERIMENTAL
Intervention: M-CT (mobile cognitive therapy) with minimal therapist support added to treatment as usual (TAU)
Number of subjects: 264

Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 264
Study: 27370526

Group type: EXPERIMENTAL
Intervention: Computer-assisted SBIRT
Number of subjects: 572

Group type: COMPARATOR
Intervention: Computer-assisted education program on nutrition (control)
Number of subjects: 572
Study: 25486369

Group type: EXPERIMENTAL
Intervention: Borderline B12 concentrations (148 to 221 pmol/L)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Low B12 (<148 pmol/L)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Normal B12 concentrations (not specified)
Number of subjects: 103
Study: 22475985

Group type: EXPERIMENTAL
Intervention: Buprenorphine plus ultra-low-dose naloxone (0.3 mg + 0.02 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Buprenorphine alone (0.3 mg)
Number of subjects: 12
Study: 20532452

Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg orally one hour prior to imaging
Number of subjects: 96

Group type: COMPARATOR
Intervention: Lemon juice (standard of care)
Number of subjects: 96
Study: 16234574

Group type: EXPERIMENTAL
Intervention: Active 40 KHz ultrasound therapy delivered by a saline mist
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham device delivering saline mist without ultrasound
Number of subjects: 55
Study: 12399142

Group type: EXPERIMENTAL
Intervention: ketamine (0.3 mg/kg; intravenous)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: haloperidol (2 mg) + ketamine (0.3 mg/kg; intravenous)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 11725662

Group type: EXPERIMENTAL
Intervention: Adhesively bonded amalgam restorations using ED Primer and Panavia 21 TC
Number of subjects: 31

Group type: COMPARATOR
Intervention: Non-bonded amalgam restorations
Number of subjects: 31
Study: 7572966

Group type: EXPERIMENTAL
Intervention: Vaccine for Haemophilus influenzae type b (Hib)
Number of subjects: 0
Study: 2301090

Group type: EXPERIMENTAL
Intervention: Metoprolol (Seloken) administered once or twice daily
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: General Health Questionnaire (GHQ)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 303
Study: 6993207

Group type: EXPERIMENTAL
Intervention: 99mTc‐sulphur colloid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 99mTc‐tin colloid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 99mTc phytate colloid
Number of subjects: 0
Study: 31543373

Group type: EXPERIMENTAL
Intervention: n-3 PUFA (2 g, ×2)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (olive oil, 2 g ×2)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: n-3 PUFA
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 31024122

Group type: EXPERIMENTAL
Intervention: Reduced receptor type‐specific actions of dopamine in women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced receptor type‐specific actions of dopamine in men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neural reward system activity during prosocial decisions
Number of subjects: 0
Study: 25870186

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 22
Study: 23812551

Group type: EXPERIMENTAL
Intervention: Arginine-supplemented enteral nutrition (9.0 g/L)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard enteral nutrition
Number of subjects: 73
Study: 21367943

Group type: EXPERIMENTAL
Intervention: Whey protein (20 g)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Casein (20 g)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Casein hydrolysate (20 g)
Number of subjects: 48
Study: 19737620

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 mcg) once daily
Number of subjects: 676

Group type: COMPARATOR
Intervention: Ipratropium (26 mcg)/Albuterol (206 mcg), 2 actuations 4 times daily
Number of subjects: 676
Study: 17403721

Group type: COMPARATOR
Intervention: C-reactive protein (CRP) levels in diabetic patients vs. non-diabetic patients in OPUS-TIMI 16 (9 mg/L vs. 7.8 mg/L, P = 0.002)
Number of subjects: 2200

Group type: COMPARATOR
Intervention: MCP-1 levels in diabetic patients vs. non-diabetic patients in OPUS-TIMI 16 (190.6 pg/mL vs. 170.8 pg/mL, P = 0.04)
Number of subjects: 2200

Group type: COMPARATOR
Intervention: C-reactive protein levels in diabetic patients vs. non-diabetic patients in TACTICS-TIMI 18 (6.6 mg/L vs. 5.2 mg/L, P = 0.0005)
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Risk associated with C-reactive protein greater than or equal to the median in diabetic patients vs. non-diabetic patients in OPUS-TIMI 16 (adjusted HR 1.63, 95% CI 1.20-2.23, P = 0.002)
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Risk associated with a 1 mmol/L increase in glucose among those with CRP greater than or equal to the median (HR 1.07, 95% CI 1.03-1.11) vs. those with CRP less than the median (HR 1.02, 95% CI 0.97-1.06)
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Synergistic relationship between glucose and C-reactive protein on clinical outcomes
Number of subjects: 2200
Study: 15110367

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.015 mg.k(‐1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.09 mg.k(‐1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 90
Study: 11255446

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/d
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/d followed by 10 mg/d
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 763

Group type: COMPARATOR
Intervention: Placebo (after 6-week washout)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 763
Study: 9398110

Group type: EXPERIMENTAL
Intervention: Imidapril
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8423906

Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg twice a day
Number of subjects: 603

Group type: COMPARATOR
Intervention: Aspirin 650 mg twice a day
Number of subjects: 603
Study: 3122887

Group type: EXPERIMENTAL
Intervention: Interim discharge summary delivered by hand
Number of subjects: 289

Group type: COMPARATOR
Intervention: Interim discharge summary posted by the hospital
Number of subjects: 289
Study: 29524451

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24IU)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 27260219

Group type: EXPERIMENTAL
Intervention: CDP with Kinesio Textape
Number of subjects: 10

Group type: COMPARATOR
Intervention: CDP with bandage
Number of subjects: 10
Study: 24731498

Group type: EXPERIMENTAL
Intervention: No antibiotics (n = 192)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Antibiotics (n = 134)
Number of subjects: 326
Study: 23886062

Group type: EXPERIMENTAL
Intervention: 2-sided news coverage (positive and negative information)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1-sided news coverage (unanimously positive information)
Number of subjects: 0
Study: 20588187

Group type: EXPERIMENTAL
Intervention: 0.6 mg/h transdermal nitroglycerin (TGTN)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.05 mg/h transdermal nitroglycerin (TGTN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sublingual nitroglycerin and inhaled salbutamol
Number of subjects: 30
Study: 18841285

Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg loading dose (LD) / 10 mg maintenance dose (MD)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Clopidogrel 600 mg loading dose (LD) / 75 mg maintenance dose (MD)
Number of subjects: 110
Study: 16631056

Group type: EXPERIMENTAL
Intervention: AcrySof Natural intraocular lens (SN60AT)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: AcrySof intraocular lens (SA60AT)
Number of subjects: 13
Study: 14583122

Group type: EXPERIMENTAL
Intervention: Therapeutic virtual environments derived from computer games (TVEDG)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Non-phobic control participants
Number of subjects: 26
Study: 11371659

Group type: EXPERIMENTAL
Intervention: Combined immunoadsorption and intravenous immunoglobulins (n=17)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Immunoadsorption alone (Control group, n=18)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Infusion of immunoglobulins at a dose of 0.14 g/kg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Immunoglobulin administration
Number of subjects: 35
Study: 9236347

Group type: EXPERIMENTAL
Intervention: Tepid temperature (34 degrees C)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Moderate hypothermia (28 degrees C)
Number of subjects: 18
Study: 7963604

Group type: EXPERIMENTAL
Intervention: Single layer mass closure with monofilament nylon
Number of subjects: 160

Group type: COMPARATOR
Intervention: Layer closure with chromic catgut
Number of subjects: 160
Study: 2956870

Group type: EXPERIMENTAL
Intervention: Enoximone (MDL 17,043) 50, 75, 100, 150 or 200 mg (mean dose 1.46 +/- 0.16 mg/kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Enoximone (MDL 17,043)
Number of subjects: 14
Study: 30037519

Group type: EXPERIMENTAL
Intervention: NIPPV with nasal cannula (NC) at 15 L/min of oxygen
Number of subjects: 37

Group type: COMPARATOR
Intervention: NIPPV alone
Number of subjects: 37
Study: 27904973

Group type: EXPERIMENTAL
Intervention: CYP3A4-metabolized statins (group A, n=725)
Number of subjects: 1187

Group type: COMPARATOR
Intervention: Non-CYP3A4-metabolized statins (group B, n=462)
Number of subjects: 1187

Group type: EXPERIMENTAL
Intervention: CYP3A4-metabolized statins (group A, n=725) with high baseline PRU
Number of subjects: 1187

Group type: COMPARATOR
Intervention: Non-CYP3A4-metabolized statins (group B, n=462) with high baseline PRU
Number of subjects: 1187

Group type: EXPERIMENTAL
Intervention: CYP3A4-metabolized statins and non-CYP3A4-metabolized statins
Number of subjects: 1187
Study: 25818472

Group type: EXPERIMENTAL
Intervention: DSMS program
Number of subjects: 403

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 403
Study: 23690996

Group type: EXPERIMENTAL
Intervention: Severity-based treatment protocols
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Treatment (specific gene expression profiling)
Number of subjects: 22
Study: 21698485

Group type: EXPERIMENTAL
Intervention: Women after standard TKA
Number of subjects: 494

Group type: COMPARATOR
Intervention: Men after standard TKA
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Women and Men after standard TKA
Number of subjects: 494
Study: 18277832

Group type: EXPERIMENTAL
Intervention: Women's‐only motivational interviewing
Number of subjects: 182

Group type: COMPARATOR
Intervention: Traditional CR group
Number of subjects: 182
Study: 17138506

Group type: EXPERIMENTAL
Intervention: Propensity score analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analytic techniques
Number of subjects: 0
Study: 12925845

Group type: EXPERIMENTAL
Intervention: ACAM1000
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dryvax
Number of subjects: 0
Study: 10615845

Group type: EXPERIMENTAL
Intervention: Plasma beta-carotene levels (quintiles)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Plasma alpha-tocopherol levels
Number of subjects: 987

Group type: COMPARATOR
Intervention: Control group (no respiratory symptoms)
Number of subjects: 987
Study: 9411502

Group type: EXPERIMENTAL
Intervention: Dexamethasone therapy (0.4 mg/kg every 12 hours for 2 days, started 10 minutes before the first antibiotic dose)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Non-steroid treated patients
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Patients with bacterial meningitis
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: All patients with meningitis
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Increased production of NO in the CSF compartment during the acute phase of BM
Number of subjects: 151
Study: 31718683

Group type: EXPERIMENTAL
Intervention: Shoulder-Café intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Shoulder-Guidance intervention (active control)
Number of subjects: 120
Study: 28770549

Group type: EXPERIMENTAL
Intervention: Sono-electro-magnetic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26600173

Group type: EXPERIMENTAL
Intervention: 60 min long 2.4 GHz Wi-Fi exposure
Number of subjects: 25
Study: 24580570

Group type: EXPERIMENTAL
Intervention: PMTO (n=51)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Community services (n=51)
Number of subjects: 102
Study: 21385862

Group type: EXPERIMENTAL
Intervention: 10 mg/day of rosuvastatin added to 80 mg/day of valsartan (ARB)
Number of subjects: 124

Group type: COMPARATOR
Intervention: ARB monotherapy (80 mg/day of valsartan)
Number of subjects: 124
Study: 18703220

Group type: EXPERIMENTAL
Intervention: One-time meeting with a psychologist discussing issues and concerns about cancer diagnosis
Number of subjects: 100

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: One-time meeting with a psychologist
Number of subjects: 100
Study: 15936063

Group type: EXPERIMENTAL
Intervention: Scopolamine (muscarinic antagonism)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mecamylamine (nicotinic antagonism)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mecamylamine + Scopolamine (simultaneous antagonism)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12
Study: 11753134

Group type: EXPERIMENTAL
Intervention: Therapeutic strategies other than antimicrobials for urinary tract infection management in postmenopausal women due to vaginal estrogen deficiency.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Management of clinical deterioration in long-term care facility residents with positive urine cultures.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urine culture as a diagnostic tool.
Number of subjects: 0
Study: 10695503

Group type: EXPERIMENTAL
Intervention: Strict bed rest for 8 days
Number of subjects: 126

Group type: COMPARATOR
Intervention: Mobilised (control group)
Number of subjects: 126
Study: 8690778

Group type: EXPERIMENTAL
Intervention: Dog and monkey sera used as blocking antibodies against mouse anti-hsCR1 monoclonal antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human sera (blood group antisera: anti-Knops, anti-McCoy, anti-Knops/McCoy, anti-Swain-Langley)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mouse, rat, dog antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hsCR1
Number of subjects: 0